We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Motivational Enhancement to Improve Treatment Engagement and Outcome in Subjects Seeking Treatment for Substance Abuse - 1

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00032981
Recruitment Status : Completed
First Posted : April 8, 2002
Last Update Posted : January 12, 2017
Information provided by:
National Institute on Drug Abuse (NIDA)

Brief Summary:
The purpose of this study is to evaluate the therapeutic usefulness of incorporating Motivational Enhancement Treatment into the standard drug abuse treatment entry process of Community Treatment Programs on improving treatment engagement, retention, and outcome.

Condition or disease Intervention/treatment Phase
Substance-Related Disorders Behavioral: Behavior Therapy Phase 3

Detailed Description:
Participants seeking treatment at the participating CTPs will be randomly assigned to either "standard" or "MET/MI" treatment, with a 1- and 3-month follow-up. Primary outcome measures will include (1) treatment retention (e.g., number of sessions/weeks completed, the rate of patients completing 3 or more subsequent sessions, and (2) substance use (e.g., urinalyses, days of opioid, cocaine, marijuana, alcohol use, rates of abstinence). Secondary outcomes will include motivation, psychosocial functioning, HIV risk behaviors, treatment utilization, and patient satisfaction. Process assessments will include measures of the working alliance as well as therapist adherence/competence ratings which will evaluate how effectively MET/MI was implemented. Participating CTPs will implement one of two independent protocols, depending on which is the best suited or feasible for the intake procedures at their clinic. Thus, following an invitation to participate, explanation of the study, and provision of informed consent, patients would complete a brief assessment battery followed by either: 1) Random assignment to 3 individual sessions of standard treatment (treatment as usual) at the program versus 3 individual sessions of MET. or 2) Random assignment to 1 individual standard assessment/evaluation session.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 561 participants
Allocation: Randomized
Primary Purpose: Treatment
Official Title: Motivational Enhancement Treatment (MET) to Improve Treatment Engagement and Outcome in Subjects Seeking Treatment for Substance Abuse
Study Start Date : May 2001
Actual Primary Completion Date : August 2004
Actual Study Completion Date : August 2004

Resource links provided by the National Library of Medicine

Primary Outcome Measures :
  1. Drug use
  2. Retention
  3. HIV risk behaviors
  4. Psychosocial functioning

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 99 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

Individuals will be eligible for the protocol who:

  • Are seeking outpatient treatment for any substance use disorder
  • Are willing to participate in the protocol (e.g., to be randomized to treatment, be contacted for follow-up assessment, to have their sessions audiotaped)
  • Are able to understand and provide written informed consent

Exclusion Criteria:

Individuals will be excluded who:

  • Are not sufficiently medically or psychiatrically stable to participate in outpatient treatment
  • Are seeking detoxification only, methadone maintenance treatment or residential inpatient treatment

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00032981

Layout table for location information
United States, California
Haight Ashbury Free Clinics
San Francisco, California, United States, 94117
Tarzana Treatment Center
Tarzana, California, United States, 91356
United States, Connecticut
CT Renaissance, Inc.
Norwalk, Connecticut, United States, 06852
LMG Programs, Inc.
Stamford, Connecticut, United States, 06901
United States, Pennsylvania
Rehab After Work
Philadelphia, Pennsylvania, United States, 19103
Northeast Treatment Center
Philadelphia, Pennsylvania, United States, 19123
Sponsors and Collaborators
Yale University
Layout table for investigator information
Principal Investigator: Kathleen Carroll, Ph.D. VA Connecticut Healthcare System
Layout table for additonal information
Responsible Party: Kathleen Carroll, Ph.D., Yale University School of Medicine
ClinicalTrials.gov Identifier: NCT00032981    
Obsolete Identifiers: NCT00016770
Other Study ID Numbers: NIDA-CTN-0004-1
First Posted: April 8, 2002    Key Record Dates
Last Update Posted: January 12, 2017
Last Verified: April 2010
Keywords provided by National Institute on Drug Abuse (NIDA):
substance use disorder
Additional relevant MeSH terms:
Layout table for MeSH terms
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders